retatrutide triple agonist weight loss trial hormone receptor for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Achieve Your Weight Loss Goals
Description
Patients should discuss eligibility and local availability with their GP or specialist diabetes/weight management service
It is their body
The LEAD-3 study found that liraglutide monotherapy reduced glycosylated hemoglobin (A1C), body weight, and blood pressure compared to glimepiride (36)
(I) Equal amounts of protein lysates from astrocytes treated with 0.1 mM HO for 1 h in vitro were immunoprecipitated using an anti-YAP1 antibody and probed with the indicated antibodies
